Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder

Journal of Affective Disorders

Volumn 170, Issue , 2015, Pages 230-236

  Blum, Steven I ^a   Tourkodimitris, Stavros ^b   Ruth, Adam ^c  

^a GLAXOSMITHKLINE   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Prescott Medical Communications Group   (United States)

Author keywords

Health outcomes; Levomilnacipran ER; Major depressive disorder; Serotonin and norepinephrine reuptake inhibitor; SF 36

Indexed keywords

MILNACIPRAN; PLACEBO; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE; DELAYED RELEASE FORMULATION;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HEALTH; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SINGLE BLIND PROCEDURE; SOCIAL INTERACTION; WELLBEING; ADOLESCENT; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DEPRESSIVE DISORDER, MAJOR; HEALTH STATUS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SOCIAL BEHAVIOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SOCIAL BEHAVIOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907930265     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.09.005     Document Type: Article

References (34)

1. APA (Text Revision) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition 2000 American Psychiatric Association Washington DC
2. G. Asnis, A. Bose, C. Gommoll, C. Chen, and W.M. Greenberg The efficacy and safety of levomilnacipran SR 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase III, randomized, double-blind, placebo-controlled study J. Clin. Psychiatry 74 2013 242 248
3. A.L. Auclair, J.C. Martel, M.B. Assie, L. Bardin, P. Heusler, D. Cussac, M. Marien, A. Newman-Tancredi, J.A. O'Connor, and R. Depoortere Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety Neuropharmacology 70 2013 338 347
4. D. Bakish, A. Bose, C. Gommoll, C. Chen, R. Nunez, W.M. Greenberg, M. Liebowitz, and A. Khan Levomilnacipran ER 40 mg and 80 mg in major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study J. Psychiatry Neurosci. 39 2014 40 49
5. P. Bech Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs 19 2005 313 324
6. J. Brazier, T. Usherwood, R. Harper, and K. Thomas Deriving a preference-based single index from the UK SF-36 Health Survey J. Clin. Epidemiol. 51 1998 1115 1128
7. J.L. Coulehan, H.C. Schulberg, M.R. Block, M.J. Madonia, and E. Rodriguez Treating depressed primary care patients improves their physical, mental, and social functioning Arch. Intern. Med. 157 1997 1113 1120
8. C. Faravelli, A. Ambonetti, S. Pallanti, and A. Pazzagli Depressive relapses and incomplete recovery from index episode Am. J. Psychiatry 143 1986 888 891
9. G.A. Fava, C. Ruini, and C. Belaise The concept of recovery in major depression Psychol. Med. 37 2007 307 317
10. M. Fava, L.M. Graves, F. Benazzi, M.J. Scalia, D.V. Iosifescu, J.E. Alpert, and G.I. Papakostas A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment J. Clin. Psychiatry 67 2006 1754 1759
11. P.K. Gandhi, L.D. Ried, A. Bibbey, and I.C. Huang SF-6D utility index as measure of minimally important difference in health status change J. Am. Pharm. Assoc.: JAPhA 52 2012 34 42
12. O.C. Gleason, W.R. Yates, M.D. Isbell, and M.A. Philipsen An open-label trial of citalopram for major depression in patients with hepatitis C J. Clin. Psychiatry 63 2002 194 198
13. G.M. Goodwin Depression and associated physical diseases and symptoms Dialogues Clin. Neurosci. 8 2006 259 265
14. C.J. Guico-Pabia, R.S. Fayyad, and C.N. Soares Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis Int. Clin. Psychopharmacol. 27 2012 1 7
15. J.H. Heiligenstein, J.E. Ware Jr., K.M. Beusterien, P.J. Roback, C. Andrejasich, and G.D. Tollefson Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression Int. Psychogeriatr. 7 Suppl 1995 125 137
16. R.M. Hirschfeld, S.A. Montgomery, M.B. Keller, S. Kasper, A.F. Schatzberg, H.J. Moller, D. Healy, D. Baldwin, M. Humble, M. Versiani, R. Montenegro, and M. Bourgeois Social functioning in depression: a review J. Clin. Psychiatry 61 2000 268 275
17. L.L. Judd, and H.S. Akiskal Delineating the longitudinal structure of depressive illness: beyond clinical subtypes and duration thresholds Pharmacopsychiatry 33 2000 3 7
18. L.L. Judd, H.S. Akiskal, P.J. Zeller, M. Paulus, A.C. Leon, J.D. Maser, J. Endicott, W. Coryell, J.L. Kunovac, T.I. Mueller, J.P. Rice, and M.B. Keller Psychosocial disability during the long-term course of unipolar major depressive disorder Arch. Gen. Psychiatry 57 2000 375 380
19. R.C. Kessler, P. Berglund, O. Demler, R. Jin, D. Koretz, K.R. Merikangas, A.J. Rush, E.E. Walters, and P.S. Wang The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA 289 2003 3095 3105
20. K. Kroenke, S.L. West, R. Swindle, A. Gilsenan, G.J. Eckert, R. Dolor, P. Stang, X.H. Zhou, R. Hays, and M. Weinberger Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial JAMA 286 2001 2947 2955
21. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med. 3 2006 e442
22. P.E. McKnight, and T.B. Kashdan The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research Clin. Psychol. Rev. 29 2009 243 259
23. S.A. Montgomery, and M. Asberg A new depression scale designed to be sensitive to change Br. J. Psychiatry 134 1979 382 389
24. J.M. Russell, L.M. Koran, J. Rush, R.M. Hirschfeld, W. Harrison, E.S. Friedman, S. Davis, and M. Keller Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression Depress. Anxiety 13 2001 18 27
25. A. Sambunaris, A. Bose, C. Gommoll, C. Chen, W.M. Greenberg, S.R. Zukin, and D.V. Sheehan A Phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran ER in patients with major depressive disorder J. Clin. Psychopharmacol. 34 2013 47 56
26. D.V. Sheehan, K. Harnett-Sheehan, and B.A. Raj The measurement of disability Int. Clin. Psychopharmacol. 11 Suppl 3 1996 89 95
27. G.E. Simon, M. VonKorff, J.H. Heiligenstein, D.A. Revicki, L. Grothaus, W. Katon, and E.H. Wagner Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants JAMA 275 1996 1897 1902
28. D.A. Solomon, A.C. Leon, J. Endicott, T.I. Mueller, W. Coryell, M.T. Shea, and M.B. Keller Psychosocial impairment and recurrence of major depression Compr. Psychiatry 45 2004 423 430
29. E. Souetre, P. Martin, H. Lozet, and H. Monteban Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants Int. Clin. Psychopharmacol. 11 1996 45 52
30. J. Spijker, R. Graaf, R.V. Bijl, A.T. Beekman, J. Ormel, and W.A. Nolen Functional disability and depression in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS) Acta Psychiatr. Scand. 110 2004 208 214
31. M.H. Trivedi The link between depression and physical symptoms Prim. Care Companion J. Clin. Psychiatry 6 2004 12 16
32. J.E. Ware Jr. SF-36 health survey update Spine (Phila Pa 1976) 25 2000 3130 3139
33. ® health survey 2nd ed. 2007 QualityMetric Incorporated Lincoln, RI
34. J.E. Ware Jr., and C.D. Sherbourne The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med. Care 30 1992 473 483